Translational Development Acquisition Corp.

Translational Development Acquisition Corp. (TDAC) is a blank-check company targeting opportunities in the life sciences and healthcare sector, with its name signaling an emphasis on translational development — the scientific pathway from laboratory research to clinical or commercial application. The company filed an 8-K with the U.S. Securities and Exchange Commission on May 27, 2026, under accession number 0001104659-26-066599, representing a notable disclosure event in its SPAC lifecycle. TDAC operates in a competitive field of healthcare-focused blank-check vehicles as it works toward completing a business combination. For full filing history, sponsor details, deal-status tracking, and deeper analytics on TDAC, sign up for a free account at SpacDesk.